MedTrace Logo

Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects

NCT01103726 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2011-11-16

No results posted yet for this study

Summary

We hypothesize that PF-02545920 will increase glucose metabolism in a part of the brain called the striatum.

Conditions

  • Healthy

Interventions

DRUG

PF-02545920

1 and 5 mg tablets, 6 mg single dose

DRUG

placebo

matching placebo tablets, single dose

DRUG

PF-02545920

1 mg tablets, 3 mg single dose

DRUG

PF-02545920

5 mg tablets, 15 mg single dose

DRUG

Placebo

matching placebo tablets, single dose

Sponsors & Collaborators

  • Yale University

    collaborator OTHER

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01103726 on ClinicalTrials.gov